{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T14:00:14Z","timestamp":1718719214216},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T00:00:00Z","timestamp":1338854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10147-012-0410-z","type":"journal-article","created":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T02:23:03Z","timestamp":1338862983000},"page":"510-516","source":"Crossref","is-referenced-by-count":5,"title":["Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients"],"prefix":"10.1007","volume":"18","author":[{"given":"Sergio","family":"Frustaci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Buonadonna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Turchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Corona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianna","family":"Tabaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GianMaria","family":"Miolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Torrisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Lo Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Tumolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,5]]},"reference":[{"key":"410_CR1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3748\/wjg.v12.i3.354","volume":"12","author":"KD Crew","year":"2006","unstructured":"Crew KD, Neugut AI (2006) Epidemiology of gastric cancer. World J Gastroenterol 12:354\u2013362","journal-title":"World J Gastroenterol"},{"key":"410_CR2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0959-8049(98)00329-3","volume":"34","author":"J Faivre","year":"1998","unstructured":"Faivre J, Forman D, Est\u00e8ve J, Gatta G (1998) Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer 34:2167\u20132175","journal-title":"Eur J Cancer"},{"key":"410_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","volume":"72","author":"AM Murad","year":"1993","unstructured":"Murad AM, Santiago FF, Petroianu A et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37\u201341","journal-title":"Cancer"},{"key":"410_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bjc.1995.114","volume":"71","author":"S Pyrh\u00f6nen","year":"1995","unstructured":"Pyrh\u00f6nen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587\u2013591","journal-title":"Br J Cancer"},{"key":"410_CR5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1008243606668","volume":"8","author":"B Glimelius","year":"1997","unstructured":"Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163\u2013168","journal-title":"Ann Oncol"},{"key":"410_CR6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/02841860151116385","volume":"40","author":"KG Janunger","year":"2001","unstructured":"Janunger KG, Hafstrom L, Nygren P et al (2001) A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 40:309\u2013326","journal-title":"Acta Oncol"},{"key":"410_CR7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0959-8049(97)86090-X","volume":"15","author":"A Webb","year":"1997","unstructured":"Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin and fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261\u2013267","journal-title":"J Clin Oncol"},{"key":"410_CR8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36\u201346","journal-title":"N Engl J Med"},{"key":"410_CR9","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2006.08.0135","volume":"25","author":"AD Roth","year":"2007","unstructured":"Roth AD, Fazio N, Stupp R et al (2007) Docetaxel, cisplatin and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25:3217\u20133223","journal-title":"J Clin Oncol"},{"key":"410_CR10","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Cutsem Van","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991\u20134997","journal-title":"J Clin Oncol"},{"key":"410_CR11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1054\/bjoc.2000.1160","volume":"83","author":"L Pronk","year":"2000","unstructured":"Pronk L, Vasey PA, Sparreboom A et al (2000) A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 83:22\u201329","journal-title":"Br J Cancer"},{"key":"410_CR12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/02841860310015894","volume":"42","author":"P Pfeiffer","year":"2003","unstructured":"Pfeiffer P, Hahn P, Jensen HA (2003) Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. Acta Oncol 42:832\u2013836","journal-title":"Acta Oncol"},{"key":"410_CR13","first-page":"1013","volume":"4","author":"N Sawada","year":"1998","unstructured":"Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human xenografts. Clin Cancer Res 4:1013\u20131019","journal-title":"Clin Cancer Res"},{"key":"410_CR14","unstructured":"See Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003. ( http:\/\/ctep.cancer.gov ). Publication date: December 12, 2003"},{"issue":"3\u20134","key":"410_CR15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cca.2010.11.010","volume":"412","author":"G Corona","year":"2011","unstructured":"Corona G, Elia C, Casetta B et al (2011) High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry. Clin Chim Acta 412(3\u20134):358\u2013364","journal-title":"Clin Chim Acta"},{"key":"410_CR16","doi-asserted-by":"crossref","unstructured":"Grothe W, Hofheinz RD, Mantovani L et al. Phase I trial of docetaxel, oxaliplatin and capecitabine (TEX) in patients with metastatic gastric cancer. J Clin Oncol 2006, ASCO annual meeting proceedings, vol 24, No 18S (June 20 Supplement), 2006:1405","DOI":"10.1200\/jco.2006.24.18_suppl.14051"},{"key":"410_CR17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/COC.0b013e318042d582","volume":"30","author":"D Evans","year":"2007","unstructured":"Evans D, Miner T, Akerman P et al (2007) A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. Am J Clin Oncol 30:346\u2013349","journal-title":"Am J Clin Oncol"},{"key":"410_CR18","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3109\/02841861003767521","volume":"49","author":"M Andersen","year":"2010","unstructured":"Andersen M, Sch\u00f8nnemann KR, Yilmaz M et al (2010) Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Acta Oncol 49:1246\u20131252","journal-title":"Acta Oncol"},{"key":"410_CR19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3109\/07357901003630942","volume":"28","author":"I Malik","year":"2010","unstructured":"Malik I, Bernal P, Byrd J (2010) A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction. Cancer Invest 28:833\u2013838","journal-title":"Cancer Invest"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-012-0410-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-012-0410-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-012-0410-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T10:29:02Z","timestamp":1594204142000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-012-0410-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1007\/s10147-012-0410-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,5]]}}}